PDF(Pubmed)
Abstract：
OBJECTIVE: The aim of this analysis was to assess glycemic control before and during the coronavirus disease (COVID-19) pandemic.
METHODS: Data from 64 (main analysis) and 80 (sensitivity analysis) people with type 1 diabetes (T1D) using intermittently scanned continuous glucose monitoring (isCGM) were investigated retrospectively. The baseline characteristics were collected from electronic medical records. The data were examined over three periods of three months each: from 16th of March 2019 until 16th of June 2019 (pre-pandemic), from 1st of December 2019 until 29th of February 2020 (pre-lockdown) and from 16th of March 2020 until 16th of June 2020 (lockdown 2020), representing the very beginning of the COVID-19 pandemic and the first Austrian-wide lockdown.
RESULTS: For the main analysis, 64 individuals with T1D (22 female, 42 male), who had a mean glycated hemoglobin (HbA1c) of 58.5 mmol/mol (51.0 to 69.3 mmol/mol) and a mean diabetes duration 13.5 years (5.5 to 22.0 years) were included in the analysis. The time in range (TIR[70-180mg/dL]) was the highest percentage of measures within all three studied phases, but the lockdown 2020 phase delivered the best data in all these cases. Concerning the time below range (TBR[<70mg/dL]) and the time above range (TAR[>180mg/dL]), the lockdown 2020 phase also had the best values. Regarding the sensitivity analysis, 80 individuals with T1D (26 female, 54 male), who had a mean HbA1c of 57.5 mmol/mol (51.0 to 69.3 mmol/mol) and a mean diabetes duration of 12.5 years (5.5 to 20.7 years), were included. The TIR[70-180mg/dL] was also the highest percentage of measures within all three studied phases, with the lockdown 2020 phase also delivering the best data in all these cases. The TBR[<70mg/dL] and the TAR[>180mg/dL] underscored the data in the main analysis.
CONCLUSIONS: Superior glycemic control, based on all parameters analyzed, was achieved during the first Austrian-wide lockdown compared to prior periods, which might be a result of reduced daily exertion or more time spent focusing on glycemic management.
METHODS: Data from 64 (main analysis) and 80 (sensitivity analysis) people with type 1 diabetes (T1D) using intermittently scanned continuous glucose monitoring (isCGM) were investigated retrospectively. The baseline characteristics were collected from electronic medical records. The data were examined over three periods of three months each: from 16th of March 2019 until 16th of June 2019 (pre-pandemic), from 1st of December 2019 until 29th of February 2020 (pre-lockdown) and from 16th of March 2020 until 16th of June 2020 (lockdown 2020), representing the very beginning of the COVID-19 pandemic and the first Austrian-wide lockdown.
RESULTS: For the main analysis, 64 individuals with T1D (22 female, 42 male), who had a mean glycated hemoglobin (HbA1c) of 58.5 mmol/mol (51.0 to 69.3 mmol/mol) and a mean diabetes duration 13.5 years (5.5 to 22.0 years) were included in the analysis. The time in range (TIR[70-180mg/dL]) was the highest percentage of measures within all three studied phases, but the lockdown 2020 phase delivered the best data in all these cases. Concerning the time below range (TBR[<70mg/dL]) and the time above range (TAR[>180mg/dL]), the lockdown 2020 phase also had the best values. Regarding the sensitivity analysis, 80 individuals with T1D (26 female, 54 male), who had a mean HbA1c of 57.5 mmol/mol (51.0 to 69.3 mmol/mol) and a mean diabetes duration of 12.5 years (5.5 to 20.7 years), were included. The TIR[70-180mg/dL] was also the highest percentage of measures within all three studied phases, with the lockdown 2020 phase also delivering the best data in all these cases. The TBR[<70mg/dL] and the TAR[>180mg/dL] underscored the data in the main analysis.
CONCLUSIONS: Superior glycemic control, based on all parameters analyzed, was achieved during the first Austrian-wide lockdown compared to prior periods, which might be a result of reduced daily exertion or more time spent focusing on glycemic management.
摘要：
目的：本分析的目的是评估冠状病毒病（COVID-19）大流行之前和期间的血糖控制。
方法：回顾性调查了使用间歇性扫描连续血糖监测（isCGM）的64例（主要分析）和80例（敏感性分析）1型糖尿病（T1D）患者的数据。从电子病历中收集基线特征。这些数据在三个时期进行了检查，每个时期为三个月：从2019年3月16日至2019年6月16日(大流行前)，从2019年12月1日至2020年2月29日（封锁前），从2020年3月16日至2020年6月16日（封锁2020年），代表着COVID-19大流行的开始和第一次奥地利范围内的封锁。
结果：对于主要分析，64名T1D患者（22名女性，42男），平均糖化血红蛋白(HbA1c)为58.5mmol/mol(51.0~69.3mmol/mol),平均糖尿病病程13.5年(5.5~22.0年)的患者被纳入分析.时间范围（TIR[70-180mg/dL]）是所有三个研究阶段中测量的最高百分比，但在所有这些情况下，2020年锁定阶段提供了最好的数据。关于低于范围的时间(TBR[<70mg/dL])和高于范围的时间(TAR[>180mg/dL]),2020年的封锁阶段也有最好的价值。关于敏感性分析，80名T1D患者（26名女性，54男性），平均HbA1c为57.5mmol/mol（51.0至69.3mmol/mol），平均糖尿病持续时间为12.5年（5.5至20.7年），包括在内。TIR[70-180mg/dL]也是所有三个研究阶段中最高的测量百分比，随着2020年的封锁阶段，在所有这些情况下也提供了最好的数据。TBR[<70mg/dL]和TAR[>180mg/dL]强调了主要分析中的数据。
结论：良好的血糖控制，根据分析的所有参数，与以前的时期相比，是在第一次奥地利范围内的封锁期间实现的，这可能是减少日常劳累或花费更多时间专注于血糖管理的结果。
方法：回顾性调查了使用间歇性扫描连续血糖监测（isCGM）的64例（主要分析）和80例（敏感性分析）1型糖尿病（T1D）患者的数据。从电子病历中收集基线特征。这些数据在三个时期进行了检查，每个时期为三个月：从2019年3月16日至2019年6月16日(大流行前)，从2019年12月1日至2020年2月29日（封锁前），从2020年3月16日至2020年6月16日（封锁2020年），代表着COVID-19大流行的开始和第一次奥地利范围内的封锁。
结果：对于主要分析，64名T1D患者（22名女性，42男），平均糖化血红蛋白(HbA1c)为58.5mmol/mol(51.0~69.3mmol/mol),平均糖尿病病程13.5年(5.5~22.0年)的患者被纳入分析.时间范围（TIR[70-180mg/dL]）是所有三个研究阶段中测量的最高百分比，但在所有这些情况下，2020年锁定阶段提供了最好的数据。关于低于范围的时间(TBR[<70mg/dL])和高于范围的时间(TAR[>180mg/dL]),2020年的封锁阶段也有最好的价值。关于敏感性分析，80名T1D患者（26名女性，54男性），平均HbA1c为57.5mmol/mol（51.0至69.3mmol/mol），平均糖尿病持续时间为12.5年（5.5至20.7年），包括在内。TIR[70-180mg/dL]也是所有三个研究阶段中最高的测量百分比，随着2020年的封锁阶段，在所有这些情况下也提供了最好的数据。TBR[<70mg/dL]和TAR[>180mg/dL]强调了主要分析中的数据。
结论：良好的血糖控制，根据分析的所有参数，与以前的时期相比，是在第一次奥地利范围内的封锁期间实现的，这可能是减少日常劳累或花费更多时间专注于血糖管理的结果。
